These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24418563)

  • 21. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
    Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
    J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor?
    Andrew A; Strebel K
    J Interferon Cytokine Res; 2011 Jan; 31(1):137-44. PubMed ID: 21166593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium.
    Bertram S; Dijkman R; Habjan M; Heurich A; Gierer S; Glowacka I; Welsch K; Winkler M; Schneider H; Hofmann-Winkler H; Thiel V; Pöhlmann S
    J Virol; 2013 Jun; 87(11):6150-60. PubMed ID: 23536651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BST2 Suppresses LINE-1 Retrotransposition by Reducing the Promoter Activity of LINE-1 5' UTR.
    Zhao Y; Du J; Wang Y; Wang Q; Wang S; Zhao K
    J Virol; 2022 Jan; 96(2):e0161021. PubMed ID: 34730388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication.
    Ma-Lauer Y; Zheng Y; Malešević M; von Brunn B; Fischer G; von Brunn A
    Antiviral Res; 2020 Jan; 173():104620. PubMed ID: 31634494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Vertebrate Evolution of the Host Restriction Factor Tetherin.
    Heusinger E; Kluge SF; Kirchhoff F; Sauter D
    J Virol; 2015 Dec; 89(23):12154-65. PubMed ID: 26401043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.
    Jafari M; Guatelli J; Lewinski MK
    J Virol; 2014 May; 88(9):5062-78. PubMed ID: 24574397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the endosomal ESCRT machinery in HIV-1 Vpu-induced down-regulation of BST2/tetherin.
    Janvier K; Roy N; Berlioz-Torrent C
    Curr HIV Res; 2012 Jun; 10(4):315-20. PubMed ID: 22524180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BST2/tetherin inhibition of alphavirus exit.
    Ooi YS; Dubé M; Kielian M
    Viruses; 2015 Apr; 7(4):2147-67. PubMed ID: 25912717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations accumulated in the Spike of SARS-CoV-2 Omicron allow for more efficient counteraction of the restriction factor BST2/Tetherin.
    Shi Y; Simpson S; Chen Y; Aull H; Benjamin J; Serra-Moreno R
    PLoS Pathog; 2024 Jan; 20(1):e1011912. PubMed ID: 38190411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.
    Fitzpatrick K; Skasko M; Deerinck TJ; Crum J; Ellisman MH; Guatelli J
    PLoS Pathog; 2010 Mar; 6(3):e1000701. PubMed ID: 20221443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
    Neil SJ; Zang T; Bieniasz PD
    Nature; 2008 Jan; 451(7177):425-30. PubMed ID: 18200009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A rare missense variant abrogates the signaling activity of tetherin/BST-2 without affecting its effect on virus release.
    Sauter D; Hotter D; Engelhart S; Giehler F; Kieser A; Kubisch C; Kirchhoff F
    Retrovirology; 2013 Aug; 10():85. PubMed ID: 23937976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tetherin Inhibits Cell-Free Virus Dissemination and Retards Murine Leukemia Virus Pathogenesis.
    Liberatore RA; Mastrocola EJ; Powell C; Bieniasz PD
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28381565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bst2/Tetherin Is Induced in Neurons by Type I Interferon and Viral Infection but Is Dispensable for Protection against Neurotropic Viral Challenge.
    Holmgren AM; Miller KD; Cavanaugh SE; Rall GF
    J Virol; 2015 Nov; 89(21):11011-8. PubMed ID: 26311886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vpu binds directly to tetherin and displaces it from nascent virions.
    McNatt MW; Zang T; Bieniasz PD
    PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
    Fritz JV; Tibroni N; Keppler OT; Fackler OT
    Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus.
    Mansouri M; Viswanathan K; Douglas JL; Hines J; Gustin J; Moses AV; Früh K
    J Virol; 2009 Oct; 83(19):9672-81. PubMed ID: 19605472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tetherin and its viral antagonists.
    Kuhl BD; Cheng V; Wainberg MA; Liang C
    J Neuroimmune Pharmacol; 2011 Jun; 6(2):188-201. PubMed ID: 21222046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains.
    Bego MG; Cong L; Mack K; Kirchhoff F; Cohen ÉA
    J Virol; 2016 Nov; 90(22):10236-10246. PubMed ID: 27581991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.